These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31073413)

  • 21. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients.
    Kestelyn PA; Kestelyn PG; De Bacquer D; Stevens AM
    Int Ophthalmol; 2019 Jan; 39(1):105-109. PubMed ID: 29274019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma.
    Tomić M; Kaštelan S; Soldo KM; Salopek-Rabatić J
    Biomed Res Int; 2013; 2013():603782. PubMed ID: 23971041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness.
    Hommer A; Schmidl D; Kromus M; Bata AM; Fondi K; Werkmeister RM; Baar C; Schmetterer L; Garhöfer G
    Eur J Ophthalmol; 2018 Jul; 28(4):385-392. PubMed ID: 29592773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients.
    El Hajj Moussa WG; Farhat RG; Nehme JC; Sahyoun MA; Schakal AR; Jalkh AE; Abi Karam MP; Azar GG
    J Ophthalmol; 2018; 2018():1319628. PubMed ID: 29707390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension.
    Sanford M
    Clin Drug Investig; 2014 Jul; 34(7):521-8. PubMed ID: 24895141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
    Swymer C; Neville MW
    Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease.
    Park JY; Kim BG; Kim JS; Hwang JH
    Transl Vis Sci Technol; 2018 Sep; 7(5):31. PubMed ID: 30386683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capsanthin from Capsicum annum fruits exerts anti-glaucoma, antioxidant, anti-inflammatory activity, and corneal pro-inflammatory cytokine gene expression in a benzalkonium chloride-induced rat dry eye model.
    Shanmugham V; Subban R
    J Food Biochem; 2022 Oct; 46(10):e14352. PubMed ID: 35892258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis.
    Yang XT; Zhao L; Wang LJ; Zhang Y; Liao DY; Wang JM
    Int J Ophthalmol; 2020; 13(3):474-480. PubMed ID: 32309186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding Ocular Surface Disease in Glaucoma: A Comparative Analysis of Symptoms and Objective Parameters.
    Romano J; Ferreira N; Godinho G; Tomás R; Oliveira N; Sousa JP
    Cureus; 2024 Feb; 16(2):e54070. PubMed ID: 38481920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.
    Katz G; Springs CL; Craven ER; Montecchi-Palmer M
    Clin Ophthalmol; 2010 Nov; 4():1253-61. PubMed ID: 21151330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
    Murugesan V; Dwivedi R; Saini M; Gupta V; Dada T; Vivekanandhan S
    Br J Ophthalmol; 2021 Jan; 105(1):141-148. PubMed ID: 31383648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.
    Tokuda N; Kitaoka Y; Matsuzawa A; Tsukamoto A; Sase K; Sakae S; Takagi H
    J Ophthalmol; 2017; 2017():3540749. PubMed ID: 28831305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial.
    Kim JM; Sung KR; Lee JW; Kyung H; Rho S; Kim CY
    Int J Ophthalmol; 2021; 14(10):1539-1547. PubMed ID: 34667730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana.
    Kobia-Acquah E; Gyekye GA; Antwi-Adjei EK; Koomson NY; Cobbina F; Donkor R; Akowuah PK
    J Glaucoma; 2021 Feb; 30(2):180-186. PubMed ID: 33074962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma.
    Filippelli M; Campagna G; Ciampa N; Fioretto G; Giannini R; Marino PF; dell'Omo R; Costagliola C
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.